280 related articles for article (PubMed ID: 29460007)
1. Diffuse gliomas classified by 1p/19q co-deletion, TERT promoter and IDH mutation status are associated with specific genetic risk loci.
Labreche K; Kinnersley B; Berzero G; Di Stefano AL; Rahimian A; Detrait I; Marie Y; Grenier-Boley B; Hoang-Xuan K; Delattre JY; Idbaih A; Houlston RS; Sanson M
Acta Neuropathol; 2018 May; 135(5):743-755. PubMed ID: 29460007
[TBL] [Abstract][Full Text] [Related]
2. TERT promoter mutation confers favorable prognosis regardless of 1p/19q status in adult diffuse gliomas with IDH1/2 mutations.
Arita H; Matsushita Y; Machida R; Yamasaki K; Hata N; Ohno M; Yamaguchi S; Sasayama T; Tanaka S; Higuchi F; Iuchi T; Saito K; Kanamori M; Matsuda KI; Miyake Y; Tamura K; Tamai S; Nakamura T; Uda T; Okita Y; Fukai J; Sakamoto D; Hattori Y; Pareira ES; Hatae R; Ishi Y; Miyakita Y; Tanaka K; Takayanagi S; Otani R; Sakaida T; Kobayashi K; Saito R; Kurozumi K; Shofuda T; Nonaka M; Suzuki H; Shibuya M; Komori T; Sasaki H; Mizoguchi M; Kishima H; Nakada M; Sonoda Y; Tominaga T; Nagane M; Nishikawa R; Kanemura Y; Kuchiba A; Narita Y; Ichimura K
Acta Neuropathol Commun; 2020 Nov; 8(1):201. PubMed ID: 33228806
[TBL] [Abstract][Full Text] [Related]
3. The correlation analysis of TERT promoter mutations with IDH1/2 mutations and 1p/19q detected in human gliomas.
Xu J; Xu FP; Liu ZH; Cui Q; Zhang KP; Li Z
Medicine (Baltimore); 2022 Jul; 101(29):e29668. PubMed ID: 35866817
[TBL] [Abstract][Full Text] [Related]
4. 1p/19q co-deletion status is associated with distinct tumor-associated macrophage infiltration in IDH mutated lower-grade gliomas.
Zhang Y; Xie Y; He L; Tang J; He Q; Cao Q; Cui L; Guo W; Hua K; Dimberg A; Wang L; Zhang L
Cell Oncol (Dordr); 2021 Feb; 44(1):193-204. PubMed ID: 32915415
[TBL] [Abstract][Full Text] [Related]
5. Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors.
Eckel-Passow JE; Lachance DH; Molinaro AM; Walsh KM; Decker PA; Sicotte H; Pekmezci M; Rice T; Kosel ML; Smirnov IV; Sarkar G; Caron AA; Kollmeyer TM; Praska CE; Chada AR; Halder C; Hansen HM; McCoy LS; Bracci PM; Marshall R; Zheng S; Reis GF; Pico AR; O'Neill BP; Buckner JC; Giannini C; Huse JT; Perry A; Tihan T; Berger MS; Chang SM; Prados MD; Wiemels J; Wiencke JK; Wrensch MR; Jenkins RB
N Engl J Med; 2015 Jun; 372(26):2499-508. PubMed ID: 26061753
[TBL] [Abstract][Full Text] [Related]
6. Impact of gross total resection in patients with WHO grade III glioma harboring the IDH 1/2 mutation without the 1p/19q co-deletion.
Kawaguchi T; Sonoda Y; Shibahara I; Saito R; Kanamori M; Kumabe T; Tominaga T
J Neurooncol; 2016 Sep; 129(3):505-514. PubMed ID: 27401154
[TBL] [Abstract][Full Text] [Related]
7. TERT promoter mutations contribute to subset prognostication of lower-grade gliomas.
Chan AK; Yao Y; Zhang Z; Chung NY; Liu JS; Li KK; Shi Z; Chan DT; Poon WS; Zhou L; Ng HK
Mod Pathol; 2015 Feb; 28(2):177-86. PubMed ID: 25081751
[TBL] [Abstract][Full Text] [Related]
8. Static and dynamic
Verger A; Stoffels G; Bauer EK; Lohmann P; Blau T; Fink GR; Neumaier B; Shah NJ; Langen KJ; Galldiks N
Eur J Nucl Med Mol Imaging; 2018 Mar; 45(3):443-451. PubMed ID: 29043400
[TBL] [Abstract][Full Text] [Related]
9. Multigene signature for predicting prognosis of patients with 1p19q co-deletion diffuse glioma.
Hu X; Martinez-Ledesma E; Zheng S; Kim H; Barthel F; Jiang T; Hess KR; Verhaak RGW
Neuro Oncol; 2017 Jun; 19(6):786-795. PubMed ID: 28340142
[TBL] [Abstract][Full Text] [Related]
10. Use of telomerase promoter mutations to mark specific molecular subsets with reciprocal clinical behavior in IDH mutant and IDH wild-type diffuse gliomas.
Akyerli CB; Yüksel Ş; Can Ö; Erson-Omay EZ; Oktay Y; Coşgun E; Ülgen E; Erdemgil Y; Sav A; von Deimling A; Günel M; Yakıcıer MC; Pamir MN; Özduman K
J Neurosurg; 2018 Apr; 128(4):1102-1114. PubMed ID: 28621624
[TBL] [Abstract][Full Text] [Related]
11.
Cicone F; Carideo L; Scaringi C; Arcella A; Giangaspero F; Scopinaro F; Minniti G
Ann Nucl Med; 2019 Apr; 33(4):295-302. PubMed ID: 30607877
[TBL] [Abstract][Full Text] [Related]
12. RNA editing-based classification of diffuse gliomas: predicting isocitrate dehydrogenase mutation and chromosome 1p/19q codeletion.
Chen SC; Lo CM; Wang SH; Su EC
BMC Bioinformatics; 2019 Dec; 20(Suppl 19):659. PubMed ID: 31870275
[TBL] [Abstract][Full Text] [Related]
13. Correlation between IDH, ATRX, and TERT promoter mutations in glioma.
Ohba S; Kuwahara K; Yamada S; Abe M; Hirose Y
Brain Tumor Pathol; 2020 Apr; 37(2):33-40. PubMed ID: 32227259
[TBL] [Abstract][Full Text] [Related]
14. The T2-FLAIR-mismatch sign as an imaging biomarker for IDH and 1p/19q status in diffuse low-grade gliomas: a systematic review with a Bayesian approach to evaluation of diagnostic test performance.
Goyal A; Yolcu YU; Goyal A; Kerezoudis P; Brown DA; Graffeo CS; Goncalves S; Burns TC; Parney IF
Neurosurg Focus; 2019 Dec; 47(6):E13. PubMed ID: 31786548
[TBL] [Abstract][Full Text] [Related]
15. High-grade gliomas with isocitrate dehydrogenase wild-type and 1p/19q codeleted: Atypical molecular phenotype and current challenges in molecular diagnosis.
Zheng L; Zhang M; Hou J; Gong J; Nie L; Chen X; Zhou Q; Chen N
Neuropathology; 2020 Dec; 40(6):599-605. PubMed ID: 32761642
[TBL] [Abstract][Full Text] [Related]
16. Next-Generation Sequencing Panel for 1p/19q Codeletion and IDH1-IDH2 Mutational Analysis Uncovers Mistaken Overdiagnoses of 1p/19q Codeletion by FISH.
de Biase D; Acquaviva G; Visani M; Marucci G; De Leo A; Maloberti T; Sanza V; Di Oto E; Franceschi E; Mura A; Ragazzi M; Serra S; Froio E; Bisagni A; Brandes AA; Pession A; Tallini G
J Mol Diagn; 2021 Sep; 23(9):1185-1194. PubMed ID: 34186176
[TBL] [Abstract][Full Text] [Related]
17. Telomerase Reverse Transcriptase Promoter Mutations in A Cohort Of Adult Gliomas - Clinicopathological Correlates.
Balakumar S; Pai R; Chacko AG; Patel B; Nancy R; Balakrishnan R; Sarkar S; Sampath G; Chacko G
Neurol India; 2022; 70(3):953-959. PubMed ID: 35864624
[TBL] [Abstract][Full Text] [Related]
18. IDH-mutated astrocytomas with 19q-loss constitute a subgroup that confers better prognosis.
Otani R; Uzuka T; Higuchi F; Matsuda H; Nomura M; Tanaka S; Mukasa A; Ichimura K; Kim P; Ueki K
Cancer Sci; 2018 Jul; 109(7):2327-2335. PubMed ID: 29752851
[TBL] [Abstract][Full Text] [Related]
19. A nuclear transport-related gene signature combined with IDH mutation and 1p/19q codeletion better predicts the prognosis of glioma patients.
Zhu Z; Lan Y; Wang L; Ge J; Wang J; Liu F; He Z; Zhang H; Luo M; Lin D; Tan Y; Xu Y; Luo T
BMC Cancer; 2020 Nov; 20(1):1072. PubMed ID: 33167941
[TBL] [Abstract][Full Text] [Related]
20. Classification based on mutations of TERT promoter and IDH characterizes subtypes in grade II/III gliomas.
Yang P; Cai J; Yan W; Zhang W; Wang Y; Chen B; Li G; Li S; Wu C; Yao K; Li W; Peng X; You Y; Chen L; Jiang C; Qiu X; Jiang T;
Neuro Oncol; 2016 Aug; 18(8):1099-108. PubMed ID: 26957363
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]